Clinical trial on the effect of Azyter in patients with blepharitis.

The effect of azithromicin ophthalmic solution on symptoms, signs, and markers of inflammation in patients with blepharitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20089

Enrollment

Registered

2011-12-12

Start date

2011-12-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blepharitis

Interventions

Treatment with Azyter 2 times/day for 3 days and once/day for 3 days will be given at the study group (N=15). The control group (N=15) includes patients with symptoms and signs of blepharitis as the

Eligibility

Inclusion criteria

Inclusion criteria: 1. Symptoms of blepharitis; 2. HLA-DR > 15% on conjunctival cells; 3. BUT =2; 5. Meibum quality >= 10.

Exclusion criteria

Exclusion criteria: 1. Glaucoma; 2. Ocular surface infections; 3. Corneal ulcer; 4. Conjunctival infections; 5. Treatment with anti-inflammatory drugs and cyclosporine in the 3 months preceding the study; 6. Surgical procedures in the 3 months preceding the study; 7. Antiglaucoma therapies; 8. Contact lens use 7 days before the study.

Design outcomes

Primary

Measure	Time frame
Evaluation of HLA-DR expression levels after treatment with Azyter.	—

Secondary

Measure	Time frame
Symptoms and signs of blepharitis, and level of cytokines in tears after treatment with Azyter.	—

Contacts

Public ContactStefano Barabino

Viale Benedetto XV, 5

barabino@schepens.harvard.edu+39 010 35338294

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)